摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

kojic acid-7-imidazolide | 717913-35-4

中文名称
——
中文别名
——
英文名称
kojic acid-7-imidazolide
英文别名
(5-Hydroxy-4-oxopyran-2-yl)methyl imidazole-1-carboxylate;(5-hydroxy-4-oxopyran-2-yl)methyl imidazole-1-carboxylate
kojic acid-7-imidazolide化学式
CAS
717913-35-4
化学式
C10H8N2O5
mdl
——
分子量
236.184
InChiKey
VKSCTSUDWQYNMZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.73
  • 重原子数:
    17.0
  • 可旋转键数:
    2.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    94.56
  • 氢给体数:
    1.0
  • 氢受体数:
    7.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    kojic acid-7-imidazolide三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 7.0h, 生成 KA-L-NH2
    参考文献:
    名称:
    Kojic acid–amino acid conjugates as tyrosinase inhibitors
    摘要:
    Kojic acid (KA), a well known tyrosinase inhibitor, has insufficient inhibitory activity and stability. We modified KA with amino acids and screened their tyrosinase inhibitory activity. Among them, kojic acid-phenylalanine amide (KA-F-NH2) showed the strongest inhibitory activity, which was maintained for over 3 months at 50 degrees C, and acted as a noncompetitive inhibitor as determined by kinetic analysis. It also exhibited dopachrome reducing activity. We also propose a new tyrosinase inhibition mechanism based on the docking simulation data. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.08.041
  • 作为产物:
    描述:
    曲酸N,N'-羰基二咪唑四氢呋喃 为溶剂, 以78%的产率得到kojic acid-7-imidazolide
    参考文献:
    名称:
    曲酸-氨基酸酰胺金属配合物及其抑制黑色素生成的活性。
    摘要:
    酪氨酸酶通过催化底物的氧化在黑色素合成途径的早期发挥关键作用。因此,已经在化妆品和食品工业中对酪氨酸酶抑制剂进行了深入研究,以开发色素不足剂并防止食品中的酶促褐变。以前,我们报道了曲酸-氨基酸酰胺(KA-AA-NH 2)与单独的曲酸相比显示出增强的酪氨酸酶抑制活性,但由于细胞通透性差,在细胞试验中未观察到。为了提高细胞通透性,我们制备了KA‐AA‐NH 2的铜和锌配合物,并使用FT‐IR光谱,ESI‐MS光谱和电感耦合等离子体分析对其进行了表征。然后我们证明KA‐AA‐NH 2铜配合物在Mel-Ab细胞中表现出黑色素生成抑制活性。版权所有©2011欧洲肽协会和John Wiley&Sons,Ltd.。
    DOI:
    10.1002/psc.1404
点击查看最新优质反应信息

文献信息

  • 펩타이드가 결합된 코직산 유도체를 유효성분으로 포함하는 피부 미백용 조성물
    申请人:Natuzen 주식회사 나투젠(120060421853) Corp. No ▼ 120111-0384727BRN ▼131-81-93442
    公开号:KR20170011283A
    公开(公告)日:2017-02-02
    본 발명은 펩타이드가 결합된 코직산 유도체의 피부 미백 용도에 관한 것으로, 보다 상세하게는 코직산에 펩타이드를 도입하여 제조한 코직산 유도체를 유효성분으로 포함하는 피부 미백용 조성물, 펩타이드가 결합된 코직산 유도체를 봉입한 나노리포좀 제조방법 및 이를 통해 제조된 나노리포좀에 관한 것이다. 본 발명에 따른 펩타이드가 결합된 코직산 유도체는 피부자극이 적으면서도 우수한 타이로시네이즈 저해 활성 및 멜라닌 생성 억제 활성을 가지고 있는바, 본 발명의 펩타이드가 결합된 코직산 유도체를 유효성분을 포함하는 조성물은 피부 미백을 위한 기능성 소재로서 의약품 및 화장품 산업에 유용하게 사용될 수 있다. 뿐만 아니라, 본 발명의 나노리포좀 제조방법은 미백 활성성분인 펩타이드가 결합된 코직산 유도체를 나노리포좀 내부에 안정적으로 봉입시켜 장시간 기간 경과에도 우수한 회수율을 갖는바, 이러한 방법으로 제조된 코직산 유도체 봉입 나노리포좀은 제형 안정성을 통해 시간 경과에 따른 미백 활성성분(펩타이드가 결합된 코직산 유도체)의 침전형성, 변색, 변취 등의 문제점을 개선할 수 있다.
    本发明涉及肽与柯洛酸衍生物结合的皮肤美白用途,更详细地说,涉及将肽引入柯洛酸中制备的柯洛酸衍生物作为有效成分的皮肤美白配方,以及含有结合肽的柯洛酸衍生物的纳米脂质体制备方法及由此制备的纳米脂质体。根据本发明,肽与柯洛酸衍生物结合具有较低的皮肤刺激性,同时具有优异的酪氨酸酶抑制活性和抑制黑色素生成活性。含有本发明的肽结合柯洛酸衍生物的配方作为有效成分可作为皮肤美白的功能性原料,在药品和化妆品行业中可被广泛应用。此外,本发明的纳米脂质体制备方法能够将结合了美白活性成分肽的柯洛酸衍生物稳定地封装在纳米脂质体内,具有优异的长时间回收率。通过这种方法制备的柯洛酸衍生物封装纳米脂质体通过形态稳定性,可以改善随时间推移导致的美白活性成分(结合肽的柯洛酸衍生物)的沉淀、变色、变质等问题。
  • Enhanced cell permeability of kojic acid–phenylalanine amide with metal complex
    作者:Seon-Yeong Kwak、Jin-Mi Noh、So-Hee Park、Jang-Woong Byun、Hye-Ryung Choi、Kyoung-Chan Park、Yoon-Sik Lee
    DOI:10.1016/j.bmcl.2009.11.069
    日期:2010.1
    Kojic acid–phenylalanine amide (KA–F–NH2), which showed an excellent tyrosinase inhibitory activity, did not inhibit melanogenesis in melanocyte due to its low cell permeability. To enhance its cell permeability by increasing lipophilicity, we prepared metal coordination compounds of KA–F–NH2 and characterized them by FT-IR and ICP analysis. The metal complex of KA–F–NH2 inhibited mushroom tyrosinase
    曲酸-苯丙酸酰胺(KA-F-NH 2)具有出色的酪氨酸酶抑制活性,但由于其低细胞通透性,因此不能抑制黑素细胞的黑素生成。为了通过增加亲脂性来提高其细胞通透性,我们制备了KA–F–NH 2的属配位化合物,并通过FT-IR和ICP分析对其进行了表征。KA-F-NH的属配合物2抑制蘑菇酪氨酸酶活性不亚于KA-F-NH 2中的黑素细胞和减少的黑色素含量有效。
  • Solid-phase synthesis of kojic acid-tripeptides and their tyrosinase inhibitory activity, storage stability, and toxicity
    作者:Hanyoung Kim、Jaehui Choi、Jin Ku Cho、Sun Yeou Kim、Yoon-Sik Lee
    DOI:10.1016/j.bmcl.2004.03.046
    日期:2004.6
    A small library of kojic acid-tripeptides (Ko-X1X2X3) was prepared by solid-phase parallel synthesis and assayed to evaluate their tyrosinase inhibitory activity. Most of the kojic acid-tripeptides showed better activities than kojic acid. Kojic acid-FWY was the best compound, and it exhibited 100-fold tyrosinase inhibitory activity compared with kojic acid. In addition, their storage stabilities were approximately 15 times higher and their toxicity was lower than that of kojic acid. (C) 2004 Elsevier Ltd. All rights reserved.
  • WO2023/77339
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)